-
1.发明授权Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof 有权结合蛋白质，包括特异性结合CD154的抗体，抗体衍生物和抗体片段及其用途公开(公告)号：US08293237B2
公开(公告)日：2012-10-23
申请号：US12532517
申请日：2008-03-21
申请人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
发明人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC分类号： A61K39/395 , C07K16/00 , C12N15/63 , C12N5/10 , C12P21/02
CPC分类号： C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译： 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。
-
公开(公告)号：US20110305702A1
公开(公告)日：2011-12-15
申请号：US13096263
申请日：2011-04-28
申请人： HSIENG S. LU , CHRISTOPHER J. PASZTY , MARTYN KIM ROBINSON , ALISTAIR J. HENRY , KELLY SUE WARMINGTON , JOHN LATHAM , ALASTAIR LAWSON , DAVID G. WINKLER , AARON GEORGE WINTERS
发明人： HSIENG S. LU , CHRISTOPHER J. PASZTY , MARTYN KIM ROBINSON , ALISTAIR J. HENRY , KELLY SUE WARMINGTON , JOHN LATHAM , ALASTAIR LAWSON , DAVID G. WINKLER , AARON GEORGE WINTERS
IPC分类号： A61K39/395 , A61P19/10 , A61P19/00 , C07K16/18 , C12N15/13
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/51 , C07K16/22 , C07K2317/24 , C07K2317/76 , C07K2317/92 , C12N15/63
摘要： Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
摘要翻译： 提供了与硬骨素蛋白表位有关的组合物和方法，以及硬骨素结合剂，例如能结合硬化蛋白的抗体。
-
公开(公告)号：US08003108B2
公开(公告)日：2011-08-23
申请号：US11410540
申请日：2006-04-25
申请人： Hsieng Sen Lu , Christpher Paszty , Martyn Kim Robinson , Alistair James Henry , Kelly Sue Warmington , John Latham , Alastair Lawson , David Winkler , Aaron George Winters
发明人： Hsieng Sen Lu , Christpher Paszty , Martyn Kim Robinson , Alistair James Henry , Kelly Sue Warmington , John Latham , Alastair Lawson , David Winkler , Aaron George Winters
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/51 , C07K16/22 , C07K2317/24 , C07K2317/76 , C07K2317/92 , C12N15/63
摘要： Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
摘要翻译： 提供了与硬骨素蛋白表位有关的组合物和方法，以及硬骨素结合剂，例如能结合硬化蛋白的抗体。
-
4.发明申请E.Coli Host Cells with Modified Phos/Psts Periplasmic Phosphate-binding Proteins, and Method of Manufacturing Recombinant Fabs 审中-公开具有修饰的Phos / Psts周质磷酸结合蛋白的大肠杆菌宿主细胞和重组Fab的制备方法公开(公告)号：US20100285530A1
公开(公告)日：2010-11-11
申请号：US12645064
申请日：2009-12-22
CPC分类号： C07K14/245 , C12N1/20
摘要： The present invention provides an E. coli host cell expressing a recombinant antibody characterized in that the E. coli host cell has been genetically modified in order to change at least one physical property of one or more E. coli proteins which in the wild type co-purify with said recombinant antibody.
摘要翻译： 本发明提供了表达重组抗体的大肠杆菌宿主细胞，其特征在于大肠杆菌宿主细胞已被遗传修饰以改变一种或多种大肠杆菌蛋白质的至少一种物理性质，其在野生型共 用所述重组抗体纯化。
-
5.发明申请Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity 有权通过抑制IL-17活性治疗多发性硬化症的方法公开(公告)号：US20090191200A1
公开(公告)日：2009-07-30
申请号：US12277030
申请日：2008-11-24
IPC分类号： A61K39/395 , A61P37/06
CPC分类号： C07K16/244 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K2317/55 , C07K2317/76
摘要： The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.
摘要翻译： 本发明提供了治疗和/或预防多发性硬化（MS）的方法，包括给予治疗有效量的IL-17活性抑制剂。
-
公开(公告)号：US06204007B1
公开(公告)日：2001-03-20
申请号：US08718323
申请日：1996-11-25
IPC分类号： C12N510
CPC分类号： C07K16/465 , A61K38/00 , C07K16/2854 , C07K2317/24 , C07K2319/00
摘要： This invention relates to whole antibodies of neutral isotype having specificity for E-selectin, process for their preparation (using vectors), pharmaceutical compositions containing them, and their use in therapy and diagnosis. Said antibodies are variants of natural antibodies altered in the Fc region, especially in the CH2 domain, so that the interactions with antibodies Fc receptors and complement are very low.
摘要翻译： 本发明涉及对E-选择素具有特异性的中性同种型的全抗体，其制备方法（使用载体），含有它们的药物组合物及其在治疗和诊断中的应用。 所述抗体是在Fc区，特别是在CH2结构域中改变的天然抗体的变体，使得与抗体Fc受体和补体的相互作用非常低。
-
7.发明申请BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 有权结合蛋白质，包括抗体，抗体衍生物和抗体片段，特别是CD154及其用途公开(公告)号：US20100104573A1
公开(公告)日：2010-04-29
申请号：US12532517
申请日：2008-03-21
申请人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
发明人： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/02 , A61P29/00 , A61P37/00
CPC分类号： C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译： 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。
-
8.发明授权E.coli host cells with modified PhoS/PstS periplasmic phosphate-binding proteins, and method of manufacturing recombinant fabs 有权具有修饰的PhoS / PstS周质磷酸结合蛋白的大肠杆菌宿主细胞，以及重组生产厂的制造方法公开(公告)号：US07662609B2
公开(公告)日：2010-02-16
申请号：US10531402
申请日：2003-10-15
CPC分类号： C07K14/245 , C12N1/20
摘要： The present invention provides an Ecoli host cell expressing a recombinant antibody characterized in that the Ecoli host cell has been genetically modified in order to change at least one physical property of one or more Ecoli proteins which in the wild type copurify with said recombinant antibody.
摘要翻译： 本发明提供了表达重组抗体的大肠杆菌宿主细胞，其特征在于已将遗传修饰的大肠杆菌宿主细胞改变为野生型与所述重组抗体共培养的一种或多种大肠杆菌蛋白质的至少一种物理性质。
-
公开(公告)号：US20100036091A1
公开(公告)日：2010-02-11
申请号：US12513809
申请日：2007-11-09
申请人： Martyn Kim Robinson , Christopher J. Paszty , Alastair James Henry , Alistair Lawson , Andy Popplewell
发明人： Martyn Kim Robinson , Christopher J. Paszty , Alastair James Henry , Alistair Lawson , Andy Popplewell
CPC分类号： C07K16/18 , C07K16/22 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.
摘要翻译： 提供了与硬骨素结合剂（例如能够结合硬化蛋白的抗体和多肽）相关的组合物和方法。
-
10.发明授权Method for the treatment of multiple sclerosis by inhibiting IL-17 activity 有权通过抑制IL-17活性治疗多发性硬化的方法公开(公告)号：US07931900B2
公开(公告)日：2011-04-26
申请号：US12277030
申请日：2008-11-24
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K2317/55 , C07K2317/76
摘要： The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.
摘要翻译： 本发明提供了治疗和/或预防多发性硬化（MS）的方法，包括给予治疗有效量的IL-17活性抑制剂。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.025 秒)
